ATE349534T1 - Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form - Google Patents

Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form

Info

Publication number
ATE349534T1
ATE349534T1 AT92921908T AT92921908T ATE349534T1 AT E349534 T1 ATE349534 T1 AT E349534T1 AT 92921908 T AT92921908 T AT 92921908T AT 92921908 T AT92921908 T AT 92921908T AT E349534 T1 ATE349534 T1 AT E349534T1
Authority
AT
Austria
Prior art keywords
analogues
nitroreductase
reducing
cytotoxic form
nadh
Prior art date
Application number
AT92921908T
Other languages
English (en)
Inventor
Gillian Anlezark
Roger Melton
Roger Sherwood
Thomas Connors
Frank Friedlos
Michael Jarman
Richard Knox
Anthony Mauger
Caroline Springer
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919122496A external-priority patent/GB9122496D0/en
Priority claimed from GB919122464A external-priority patent/GB9122464D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE349534T1 publication Critical patent/ATE349534T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/34—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups and esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01284—S-(hydroxymethyl)glutathione dehydrogenase (1.1.1.284), i.e. nitroreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92921908T 1991-10-23 1992-10-23 Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form ATE349534T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919122496A GB9122496D0 (en) 1991-10-23 1991-10-23 Improvements relating to cytotoxic agents
GB919122464A GB9122464D0 (en) 1991-10-23 1991-10-23 Further improvements relating to cytotoxic agents

Publications (1)

Publication Number Publication Date
ATE349534T1 true ATE349534T1 (de) 2007-01-15

Family

ID=26299729

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92921908T ATE349534T1 (de) 1991-10-23 1992-10-23 Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form

Country Status (9)

Country Link
US (3) US5633158A (de)
EP (2) EP0540263A1 (de)
JP (2) JP4115514B2 (de)
AT (1) ATE349534T1 (de)
AU (1) AU681337B2 (de)
CA (1) CA2122036C (de)
DE (1) DE69233669T2 (de)
ES (1) ES2279506T3 (de)
WO (1) WO1993008288A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
ATE361759T1 (de) * 1993-07-15 2007-06-15 Cancer Res Campaign Tech Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
JPH07155188A (ja) * 1993-12-06 1995-06-20 Chisso Corp ニトロ還元酵素遺伝子
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9422264D0 (en) * 1994-11-04 1994-12-21 Cancer Res Campaign Tech Inducible cell ablation
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
JP3632246B2 (ja) * 1995-06-19 2005-03-23 チッソ株式会社 大腸菌のフラビン還元酵素
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
WO1998022577A1 (en) * 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
AU5676398A (en) * 1997-01-31 1998-08-25 University Of Alberta, The Method for detecting exogenous gene expression
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
CA2325050A1 (en) * 1998-04-06 1999-10-14 Dalhousie University A novel nitroreductase and therapeutic uses therefor
AU757510C (en) 1998-08-27 2003-09-11 Medimmune Limited Pyrrolobenzodiazepines
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
GB9903019D0 (en) * 1999-02-10 1999-03-31 Microbiological Res Authority Nitroreductase enzymes
US20040014191A1 (en) * 1999-02-10 2004-01-22 Nigel Minton Nitroreductase enzymes
GB9909612D0 (en) * 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
GB0002261D0 (en) * 2000-02-02 2000-03-22 Amersham Pharm Biotech Uk Ltd Fluorescent detection method & reagent
JP2004500097A (ja) 2000-03-02 2004-01-08 エムエル　ラボラトリーズ　ピーエルシー Ｔｃｆ応答性エレメント
ATE483714T1 (de) 2001-12-03 2010-10-15 Universitaetsklinikum Charite Podophyllotoxine als antiproliferative mittel
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
WO2004083391A2 (en) * 2003-03-13 2004-09-30 Washington University In St. Louis Targeted and regional cellular ablation in zebrafish
GB0306908D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Bioreductively activated stilbene prodrugs
GB0306907D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
NZ565378A (en) 2005-06-29 2011-03-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
GB0517957D0 (en) * 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
JP5357049B2 (ja) * 2006-12-26 2013-12-04 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
CA2802087A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
EP2732029B1 (de) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Verfahren zur zellprogrammierung und genommanipulation
WO2014132137A2 (en) 2013-03-01 2014-09-04 Université De Genève Transgenic cell selection
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
JP7244163B2 (ja) * 2015-03-16 2023-03-22 クロマデックス，インコーポレイテッド ニコチン酸リボシドまたはニコチンアミドリボシド組成物、その還元誘導体、およびその使用
CN112359079B (zh) * 2020-11-10 2022-07-26 江苏八巨药业有限公司 一种伊马胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472312A (en) * 1979-11-07 1984-09-18 Research Corporation p-Nitrocarbobenzoxy naphthazarin
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
US4680382A (en) * 1986-02-03 1987-07-14 Trustees Of Boston University Analogues of actinomycin D
JPH0674251B2 (ja) * 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
ZA886812B (en) * 1987-11-23 1989-07-26 Bristol Myers Co Anti-tumor prodrugs
ZA886810B (en) * 1987-12-18 1989-08-30 Bristol Myers Co Epipodophyllotoxin glucoside 4'-acyl derivatives
GB8804068D0 (en) * 1988-02-22 1988-03-23 Roberts J R Improvements relating to control of neoplastic tissue growth
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten

Also Published As

Publication number Publication date
ES2279506T3 (es) 2007-08-16
EP0638123A1 (de) 1995-02-15
US5633158A (en) 1997-05-27
JP2005040136A (ja) 2005-02-17
AU681337B2 (en) 1997-08-28
CA2122036C (en) 2002-09-17
EP0540263A1 (de) 1993-05-05
US5977065A (en) 1999-11-02
DE69233669T2 (de) 2007-10-25
JPH07501692A (ja) 1995-02-23
CA2122036A1 (en) 1993-04-29
DE69233669D1 (de) 2007-02-08
JP4115514B2 (ja) 2008-07-09
EP0638123B1 (de) 2006-12-27
WO1993008288A1 (en) 1993-04-29
JP3995666B2 (ja) 2007-10-24
AU2776992A (en) 1993-05-21
US5780585A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
ATE349534T1 (de) Bakterielle nitroreduktase zur reduzierung von cb 1954 und analogen davon in eine zytotoxische form
EP0276132A3 (en) Strain of microorganism having antimicrobial activity strain of microorganism having antimicrobial activity
IL187388A0 (en) Use of a conjugate for preparing a composition for treating secondary tissue damage and other inflammatory conditions
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
DK0431350T3 (da) Ny polypeptidforbindelse og fremgangsmåde til fremstilling deraf
IL119698A0 (en) Novel 9- ([haloacyl) amido]-6-demethyl-6-deoxytetracycline intermediates
NO882269D0 (no) Fremgangsmaate til fremstilling av rekombinant pseudomonas eksotoksin som et aktivt immunotoksin med smaa bivirkninger
ID18883A (id) Pesaing 5-ht 1f
SE8904332D0 (sv) Farmaceutisk beredning foer bekaempning av patogena tarmbakterier
EP0725826B1 (de) Verbesserte krebstherapie
GR3005960T3 (de)
CA2135487A1 (en) Heteroaromatic Quinuclidinenes, Their Use and Preparation
EP0366668A4 (de) Neue bacillus thuringiensis-stämme, verfahren zu ihrer isolierung und verwandte insektizidzusammensetzungen.
HU9401511D0 (en) Vaccine against streptococcus suls infection
EP0529088A4 (de)
AU6736698A (en) Oxidised fragments of apolipoprotein b and their use
GR3022367T3 (en) Aromatic hydroxyamidine derivatives and their use as leukotriene by receptor anagonists.
TW249803B (de)
ATE134640T1 (de) Neue verbindungen, ''leusstroducsins'' gennant, ihre herstellung und therapeutische verwendungen
DE69935828D1 (de) Alkalische Ceramidase (E.C. 3.5.1.23) kodierendes Gen aus Pseudomonas aeruginosa
DE69832216D1 (de) Rantes Mutanten und deren therapeutischen Anwendungen
Kratasyuk et al. The effect of succinic acid sulfoderivatives on bacterial luminescence.
BR9403325A (pt) Plasmídeo derivado de lactobacillus delbriekii SP., vetor recombinatie, microorganismo, lactobacillus bulgaricus, e, uso do plasmídeo
Lisiecki et al. The animal body iron sources utilized in vitro by staphylococci
Pohl Verotoxigenic Escherichia coli isolated from bovines.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties